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sure by demanding early decisions and rapid access. Decision makers may unduly 
delay potential benefits to patients by waiting for stronger evidence, or may endorse 
medicines that later turn out to have a less robust benefit-risk ratio, to be ineffective, 
cost-ineffective, or even harmful. Hence, many countries have developed mechanisms 
that allow temporary access to promising medicines while concurrently requesting the 
generation of additional evidence to reduce uncertainty. Their objective is an optimal 
trade-off between different stakeholder needs, flexibility, responsiveness, and rigor as 
well as the flexibility to revise decisions on access when new evidence becomes avail-
able. The ENCePP WG on HTA has the potential to become a capacity building tool for 
regulatory and HTA agencies to develop research structures aimed at complementing 
the evidence generation for MA and market access. Post-authorisation studies devel-
oped under the auspices of ENCePP could provide new safety and clinical effectiveness 
information of marketed medicines. ENCePP expertise, research experience and health 
care databases may also contribute to the coordination, methodological guidance and 
data sourcing for the enhancement of HTA processes.
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Objectives: Main function of a health system is to prevent diseases, restore health 
status and reduce health impairment. Health systems are mainly organized on effi-
cacy based decisions, but sometimes their social functions modulate this principle. 
In case of small patient groups, end-stage status and unmet health needs, usually 
decision are made on the basis of equity, instead of efficacy. These demands create 
special development conditions; eventuate in high prices on the supply side, therefore 
cost-effectiveness cannot be guaranteed, not even with substantial health benefits. 
Numerous expensive drug therapies are available in Hungary with reimbursement, 
but due to fiscal restrictions, new therapies are not able to access reimbursement. 
These tendencies create a paradox situation, since equity is implemented occasionally 
in absence of objective criteria. Due to the huge differences among these therapies, a 
standardized decision-making principle does not exist, but a general framework can 
be developed. In our study, methods and techniques are introduced, which can help to 
assess these therapies and organize a transparent system. MethOds: For the general 
assessment of therapies, many methods are available. In our research, we reviewed 
these tools and investigated their combinability in the special situation of “high-
value” therapies. Results: A wide range of evidences (clinical trials, meta-analysis, 
health-economy analysis, HTAs) provide a robust background to compare high-value 
therapies between different therapeutic areas. Outputs (LYG, OS, QALY, costs etc.) 
show a significant variation following different clarification process. A standard-
ized process needed to earn comparable outputs from evidences. cOnclusiOns: As 
we found, these tools could help decision making on prioritizing therapies, allocate 
resources with a higher control and reduce the risk of reimbursement.
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Orphan Drug Legislation incentivises the development of treatments for rare dis-
eases that would otherwise not be profitable investment opportunities. However, 
with budgets squeezed and diseases increasingly stratified, we question whether 
this legislation is fit for purpose. Segmenting diseases into genetically-defined sub-
groups, most notably among some cancers, has enabled increased pharmacological 
targeting. Common diseases are thus being reconsidered as multiple rare conditions, 
each eligible for orphan designation, entitling the treatments to the economic ben-
efits afforded by legislation. Stratification also occurs in diseases which are already 
rare (e.g. cystic fibrosis), and new treatments, such as ivacaftor, are being developed 
to target specific mutations. Orphan status for a drug is maintained regardless of 
whether the overall population size, for which the drug is licensed, exceeds prevalence 
thresholds enabling companies to take a strategic approach to development. The high 
prices of orphan drugs impact on access. However, typical cost-effectiveness thresh-
olds are often waived suggesting that greater value is placed on treatments for rare 
conditions, compared with prevalent diseases that are equally severe and debilitating. 
Population surveys indicate that funding policies that take resources from elsewhere 
in health economy budgets to fund these treatments are not in the public interest. 
At the same time, research and development into certain common diseases such as 
stroke, where the burden is much higher, has been somewhat neglected. We believe 
it is time to revisit orphan drug legislation. Regulators should be able to limit the 
benefits of orphan designation should the cumulative eligible population exceed a 
certain threshold. More robust criteria need to be applied for defining a “medically 
plausible subset” and pricing should to be brought closer in line with drugs for non-
rare diseases. Furthermore, the focus of incentives should move more towards areas 
of unmet need where disease burden is greatest.
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In this paper, we review a well-known phenomenon of »me-too« drugs in the pharma-
ceutical branded markets, which has gained wide attention during the recent years. 
A branded “me-too” drug is deemed having somewhat similar therapeutic effect as 
the “breakthrough” drug, although from an intellectual property right perspective, 
there is no difference between the two. Definition of “me-too” drugs has yet to reach 
consensus and it would likely be ferociously disputed by the branded firms. When the 
first branded »me-too« drug enters the market, we are dealing with oligopoly, or more 
precisely, duopoly, described by Cournot model. From an oligopoly model, we would 
expect at Nash equilibrium both price to decrease and total volume to increase com-
pared to shared monopoly conditions. An oligopolistic structure of a »me-too« phar-
maceutical market puts substantial emphasis on branding and promotion (to achieve 
Objective: Pharmaceutical pricing is characterized by a consistent variability across 
markets. Social and economic differences represent only the easiest-to-predict reason 
for such variability. Stricter regulatory hurdles, market landscape, challenging nego-
tiation processes, varying business strategies, and sometimes unplanned outcomes 
of pharma launch decisions concur in the final price for a specific drug. A better 
understanding of price trends and out-patterns is a useful insight to help improving 
pricing strategies by targeting realistic pricing expectations, and studying competi-
tors’ pricing mistakes and successes. This paper shows the price variability of ten 
different pharmaceuticals in ten key markets (France, Germany, UK, Italy, Spain, US, 
Brazil, Russia, India, and China). Common trends, similarities and particularities are 
discussed. MethOds: Using PRICENTRICTM data, we collected ex-factory prices for 
various oncology products, and we defined whether a country fell into a HTA sys-
tem or free pricing group. We also compared the product prices to GDP per capita 
(International Monetary Fund 2012) to investigate trends between the two parameters. 
The analysis investigates two key areas: 1. Difference in price depends on social, eco-
nomic considerations but also by the nature and complexity of market access process 
2. The relationship between prices and GDP per capita across countries. Results: The 
US and Germany have the highest prices of all studied countries. They are also the 
only two countries where prices are freely set by manufacturers. Prices are slightly 
higher in countries having a high GDP per capita. However, countries like France and 
UK having strong HTA authorities and pricing regulations do have a small correlation 
to this trend line. cOnclusiOn: Our analysis shows that pricing and pharma strate-
gies can be based on countries’ economic situation. Nevertheless, formal established 
HTA bodies with clear pricing rules help controlling pricing.
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Collaboration with health care stakeholders is a fundamental component of a sys-
tems-based health care economy, and it will become the dominate business model 
going forward. Yet most health care industry stakeholders are failing to accept this 
inevitable transition. While many acknowledge the need to move toward a more 
integrated “systems thinking” approach – one that maps influence patterns, ampli-
fies interdependencies, and drives collective outcomes, they struggle with actual 
implementation. A viable and sustainable information network provides the struc-
ture, aligned incentives and competitive collaboration the bricks and mortar, and 
trust the cornerstone. Until they can build that and foster a culture of transparency, 
they won’t achieve the cost and innovation benefits inherent in these cross-industry 
partnerships. Although health care stakeholders know they need to partner with 
others to be successful in this new systems-thinking economy, they need actionable 
strategies to demonstrate how the benefits of ongoing collaborations far outweigh 
the risks. This podium presentation will present original research aimed to qualify 
stakeholder perceptions on alignment and collaboration around the delivery of health 
care, in addition to critical hurdles they must overcome. A recent survey of close to 
300 Biopharma executives, EU and US Payers, and US providers provides insight into 
their needs, their disparate perceptions, and their levels of confidence in the ability to 
shift to a systems-thinking collaborative culture. Approximately 25% of respondents 
stated they were not aligned with other stakeholders, though agree they need better 
alignment and foresee closer collaboration in the future. Over 70% of stakeholders 
believe data transparency and information-sharing is critically important to a suc-
cessful and interoperable health care system, yet very few from each group were 
willing to demonstrate such transparency. Further detail will be given on insights and 
challenges gleaned from interviewing large and small stakeholders as well as practical 
strategies to guide the transformation to a systems-thinking industry.
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The European Network of Centres for Pharmacoepidemiology and Pharmacovigilance 
(ENCePP) is a project led by the European Medicines Agency aimed at further strength-
ening the post-authorisation monitoring of medicinal products in Europe by facilitat-
ing the conduct of multi-centre, independent post-authorisation studies focusing on 
safety and benefit/risk assessment. ENCePP has recently established a WG on HTA 
to develop methodological guidance to supplement the efficacy and safety aspects 
of medicines known at the time of marketing authorisation (MA) and to bridge the 
needs of HTA and post-marketing benefit-risk assessments. Decision makers are often 
faced with the challenge that long-term, real-world data on safety and effectiveness is 
lacking at the time of MA. This creates uncertainty around the medicines’ risk-benefit 
profile while manufacturers, health care providers, and patient groups exert pres-
